Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company advancing targeted therapies for cardiometabolic disease.

Backed by experienced leadership and world-class investors, we are pushing a bold vision to improve outcomes for patients who remain underserved by today’s standard-of-care.

We are focused on delivering a new treatment option for patients with type 2 diabetes for whom elevated cortisol is a driver of disease progression and treatment resistance. CAPTAIN-T2D is a Phase 2b clinical trial evaluating clofutriben, a novel HSD-1 inhibitor, for treatment-resistant type 2 diabetes with elevated cortisol.